



Elderly men treated with CoreTherm® for benign prostatic hyperplasia have lower risk for a prostate cancer diagnosis later in life compared to men treated with TURP, according to a new Swedish register study

A new study published in the *Journal of Nephrology, Urology and Andrology* shows that elderly men treated with the CoreTherm® Concept for benign prostatic hyperplasia (BPH) have a lower risk of prostate cancer diagnosis later in life and a decreased risk of prostate cancer-related death compared to men treated with transurethral resection of the prostate (TURP). The study investigated men treated in Sweden with either CoreTherm® or TURP for BPH between 1999 and 2019.

Benign prostatic hyperplasia (BPH) is a common condition among older men caused by an enlarged prostate gland. When invasive treatment for BPH is considered necessary, TURP remains the standard surgical treatment. However, other procedures are available including CoreTherm® Concept which is a minimal invasive transurethral microwave thermotherapy.

BPH is a non-malignant condition but may coexist with incidental prostate cancer. The background and hypothesis for the published study was that intraprostatic hyperthermia achieved during CoreTherm® Concept treatments may kill incidental prostate cancer cells and influence prostate cancer-related occurrence and death later in life.

In the study all men treated with TURP (n= 74,527) or CoreTherm® Concept (n= 4,686) for BPH in Sweden during January 1999 and December 2019 were identified in the National Patient Register. Using the individually unique national registration numbers assigned to all Swedish citizens, the treated men were linked to the National Cancer Register and National Cause of Death Register.

The results showed that elderly men (≥ 71 years of age) treated with CoreTherm® Concept for BPH had a reduced risk for a prostate cancer diagnosis later in life compared to those treated with TURP. The results also showed that elderly men treated with CoreTherm® Concept had a significant decreased risk for prostate cancer-related death compared to patients treated with TURP.

“CoreTherm® is a well-documented treatment with excellent results for men with BPH. That we in this study have shown that CoreTherm® could also potentially influence the risk of developing and dying from prostate cancer is, of course, very interesting. There are several different mechanisms that could explain these results. One is that undiagnosed prostate cancer might be directly destroyed during the treatment. During a CoreTherm® procedure, a certain amount of heat spreads to parts of the prostate outside the intended treatment area. This increase in temperature is not sufficient to



PRESS RELEASE
27 January 2025 10:00:00 CET

damage benign prostate tissue, but cancer cells are more sensitive to heat than normal cells. This heat increase could therefore kill any undetected cancer cells, which might reduce the risk of diagnosed prostate cancer later in life. Another possible mechanism is that the heat distribution activates the cell-mediated immune response, which in turn may lead to the attack and elimination of cancer cells. However, it is important to emphasize that further studies are needed to confirm the conclusions of this study or before we radically change how we treat benign prostatic hyperplasia," said Fredrik Stenmark, the main author of the study.

"These new data showing that CoreTherm® not only effectively improves symptoms of BPH but may also influence the risk of prostate cancer later in life, further strengthen CoreTherm® as an attractive treatment option for BPH patients. With the launch of CoreTherm® Eagle, we are excited to provide clinics across Europe the opportunity to offer this proven treatment to their BPH patients" said Anders Kristensson, CEO of ProstaLund AB.

[Link to full publication.](#)

Stenmark F et al. *Does the CoreTherm® Concept Offering Transurethral Microwave Temperature Feedback Thermotherapy or Transurethral Resection of Prostate for Benign Obstruction have an Impact on Long-term Risk for Prostate Cancer Incidence and Mortality? Results from a Long time Nationwide Observational Cohort Investigation.* J Nephrol Urol Andrology. 2024;2(2):01-08.

Note: The intended use of CoreTherm® is treatment of patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). CoreTherm® is not intended for the treatment of prostate cancer.

About CoreTherm®

CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPH). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, www.coretherm.com.

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com



PRESS RELEASE
27 January 2025 10:00:00 CET

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPH). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,500 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

Elderly men treated with CoreTherm® for benign prostatic hyperplasia have lower risk for a prostate cancer diagnosis later in life compared to men treated with TURP, according to a new Swedish register study